Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q1 2018 · 10-Q
Revenue$4.78M$4.78M+935.5% vs Q1 2017 Net Income-$4.66M-$4.66MN/M vs Q1 2017 EPS Diluted-$0.18-$0.18N/M vs Q1 2017 Operating Income-$4,619,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
Free Cash Flowderived-$7,456,000N/M Margins · derivedOperating margin-96.6%+1405.4 pt vs Q1 2017
Net margin-97.4%+1413.4 pt vs Q1 2017
ended Mar 31, 2018 · filed May 9, 2018 · 39 d after period end